• Product name

    Anti-VEGF Receptor 2 (phospho Y951) antibody
    See all VEGF Receptor 2 primary antibodies
  • Description

    Rabbit polyclonal to VEGF Receptor 2 (phospho Y951)
  • Host species

  • Specificity

    This antibody is specific for VEGF Receptor 2 only when phosphorylated at tyrosine 951.
  • Tested applications

    Suitable for: WB, ELISA, IHC-P, ICC/IFmore details
  • Species reactivity

    Reacts with: Mouse, Human
    Predicted to work with: Rat
  • Immunogen

    Synthetic phosphopeptide derived from Human VEGF Receptor 2 around the phosphorylation site of tyrosine 951.

  • Positive control

    • Breast carcinoma tissue and SK-OV3 cell extract.



Our Abpromise guarantee covers the use of ab38473 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Detects a band of approximately 190 kDa (predicted molecular weight: 151 kDa).
ELISA 1/20000.
IHC-P Use at an assay dependent concentration.
ICC/IF 1/100.


  • Function

    Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Involvement in disease

    Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
  • Sequence similarities

    Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational

    Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
  • Cellular localization

  • Information by UniProt
  • Database links

  • Alternative names

    • CD309 antibody
    • CD309 antigen antibody
    • EC antibody
    • Fetal liver kinase 1 antibody
    • FLK-1 antibody
    • FLK1 antibody
    • FLK1, mouse, homolog of antibody
    • Kdr antibody
    • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
    • Kinase insert domain receptor antibody
    • KRD1 antibody
    • Ly73 antibody
    • Protein tyrosine kinase receptor FLK1 antibody
    • Protein-tyrosine kinase receptor flk-1 antibody
    • soluble VEGFR2 antibody
    • Tyrosine kinase growth factor receptor antibody
    • Vascular endothelial growth factor receptor 2 antibody
    • VEGFR 2 antibody
    • VEGFR antibody
    • VEGFR-2 antibody
    • VEGFR2 antibody
    • VGFR2_HUMAN antibody
    see all


  • ab38473 at a 1:50 dilution staining VEGF Receptor 2 in Human breast carcinoma tissue using Immunohistochemistry, Paraffin Embedded Tissue.

    Left image : untreated.

    Right image : treated with phosphopeptide.

  • All lanes : Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473) at 1/500 dilution

    Lane 1 : SK-OV3 cell extract (5-30ug of total protein).
    Lane 2 : SK-OV3 cell extract (5-30ug of total protein). Treated with phosphopeptide.

    All lanes : Alkaline Phosphatase Goat Anti-Rabbit IgG (H+L)

    Predicted band size: 151 kDa
    Observed band size: 190 kDa
    why is the actual band size different from the predicted?


This product has been referenced in:

  • Huang M  et al. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell. BMC Gastroenterol 18:169 (2018). Read more (PubMed: 30400838) »
  • Zhao G  et al. The Soluble VEGF Receptor sFlt-1 Contributes to Impaired Neovascularization in Aged Mice. Aging Dis 8:287-300 (2017). Read more (PubMed: 28580185) »
See all 6 Publications for this product

Customer reviews and Q&As

1-6 of 6 Abreviews or Q&A


We are happy to refund your purchase. However it seems that you have purchased this antibody from our distributor in Australia. Could you please contact them and ask them to request a refund from Abcam for you. If the product was in 6 month guarantee period I can then refund the whole purchase. I am sorry I can’t refund you directly because we do not have your purchase order number details. Please contact Sapphire Bioscience in Australia they will be able to help you.

Read More


Thank you for confirming these details and for your cooperation. The details provided enable us to closely monitor the quality of our products. I am sorry this product did not perform as stated on the datasheet and for the inconvenience this has caused. I can further offer you a replacement vial from different lot or a different antibody against the same target. Let me know how you would like to proceed. Looking forward to hearing from you soon.

Read More


Thank you for your enquiry regarding ab38473 and for taking the time to provide some useful details of the experiments. I am very sorry to hear that you are having problems with this antibody. The protocol looks fine to me however I would like to ask few questions which would help me identify the source of the problem; - ab38473 is a phospho specific antibody which will detect the phosphorylated VEGFR2. We have successfully used human breast carcinoma tissue for QC test of this antibody. I would suggest using human breast cancerous tissues sections as positive control. I would also suggest checking the following publication; "VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis" http://www.mendeley.com/research/vegf-receptor2-y951-signaling-role-adapter-molecule-tsad-tumor-angiogenesis/# - Optimization of antigen retrieval step can also help. I would suggest trying the 5, 15 and 20 minute’s incubation time also. - For frozen section acetone or etahnol fixatives are highly recommended. I hope these suggestions will be helpful. Let me know if the results do not improve; I will be happy to assist you further.

Read More
Immunocytochemistry/ Immunofluorescence
Mouse Cell (endothelial cells)
endothelial cells
Yes - 0.1%Triton/0.1%NP40
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 24°C

Abcam user community

Verified customer

Submitted Oct 18 2008

Immunocytochemistry/ Immunofluorescence
Mouse Cell (tumor cell)
tumor cell
Yes - 0.1% triton X 100
Blocking step
BSA as blocking agent for 30 minute(s) · Concentration: 2% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Sep 19 2007


Thank you for your patience in awaiting a response. As mentioned previously the suggested positive control is rat brain. Briefly the lysate was prepared in the following way: The test was made with whole rat brain tissue. 1) Place the tissue in a homogenizing tube which was on ice. Add extraction buffer (here RIPA buffer was used) in the tube to cover the tissue (2x more than tissue by volume). 2) Homogenize the tissue with a homogenizer on ice. 3) Centrifuge 8,000rpm for 30 min at 4 C. Take the supernatant. 4) Assay protein concentration. Apply 20 or 30 ug protein/per line on SDS-PAGE. I hope that you find this helpful. Should you continue to experience problems then please get back in touch with me again.

Read More

For licensing inquiries, please contact partnerships@abcam.com

Sign up